Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study (AI ProMiS)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ziga Spiclin, PhD
- Phone Number: 014768784
- Email: ziga.spiclin@fe.uni-lj.si
Study Locations
-
-
-
Celje, Slovenia, 3000
- General and Teaching Hospital Celje
-
Izola, Slovenia
- General Hospital Izola
-
Maribor, Slovenia, 2000
- University Medical Center Maribor
-
-
Osrednjeslovenska
-
Ljubljana, Osrednjeslovenska, Slovenia, 1000
- University Medical Center Ljubljana
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- persons diagnosed with MS (any phenotype; according to the 2010 McDonald criteria) and CIS patients
- availability of at least two MRI exams with both FLAIR and T1-weighted scans of the same participant over a period of at least 6 months at the most recent examination
- availability of demographic, clinical data and treatment information for the same participant over a period of at least 6 months at the most recent examination
- availability of EDSS score and at least one previous EDSS scores for the same participant over a period of at least 6 months at the most recent examination
Exclusion Criteria:
- other clinically relevant systemic diseases if the researcher considers them to be significant
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Atrophied lesion volume derived from MRI predicts confirmed EDSS disability progression
Time Frame: Atrophied lesion volume quantified from two or more MR scans across the span of at least one and up to five years
|
Patients will be divided into two groups based on the presence or absence of EDSS disability progression (DP) during the observation period.
The DP converters will be classified as patients with an EDSS change of at least 1.5 if the baseline EDSS is less than 1.0, those with an EDSS change of at least 1.0 if the baseline EDSS is 1.0-5.5, and those with an EDSS change of at least 0.5 if the baseline EDSS is 5.5 or higher [15].
DP converters should have confirmed progression of EDSS impairment over a period of at least 6 months.
DP non-converters include individuals who do not meet the criteria for conversion.
Atrophied lesion volume will be quantified from MR scans taken >6 months prior to the observed EDSS increase.
Advanced artificial intelligence based image analysis tools will be applied to assess the atrophied lesion volume.
|
Atrophied lesion volume quantified from two or more MR scans across the span of at least one and up to five years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Atrophied lesion volume derived from MRI predicts conversion to secondary progressive multiple sclerosis
Time Frame: Atrophied lesion volume quantified from two or more MR scans across the span of least one and up to five years
|
Patients will be divided into two groups, i.e. those who transitioned from clinically isolate syndrome (CIS) or relapsing-remitting (RR) to secondary progressive (SP) form of MS and those who were diagnosed with CIS/RRMS during the observation period.
A consilium for patients with MS will confirm the SPMS diagnosis by consensus.
Atrophied lesion volume will be quantified from MR scans taken >6 months prior to the observed conversion to the SPMS.
Advanced artificial intelligence based image analysis tools will be applied to assess the atrophied lesion volume.
|
Atrophied lesion volume quantified from two or more MR scans across the span of least one and up to five years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ziga Spiclin, PhD, University of Ljubljana
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0120-570/2021/5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.